|
Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial. |
|
|
Consulting or Advisory Role - Sanofi (Inst) |
Travel, Accommodations, Expenses - Sanofi |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Sanofi |
Travel, Accommodations, Expenses - Sanofi |
|
|
Honoraria - Bristol-Myers Squibb; Janssen-Cilag; Pfizer; Sanofi |
Consulting or Advisory Role - Janssen-Cilag; Novartis; Pfizer; Sanofi |
Speakers' Bureau - Janssen-Cilag; Pfizer; Sanofi; Sotio |
Travel, Accommodations, Expenses - Novartis; Pfizer; Sanofi |
|
|
Consulting or Advisory Role - Amgen; Novartis; Pfizer; Sanofi |
Speakers' Bureau - Novartis; Pfizer |
Research Funding - novartis; pfizer |
Travel, Accommodations, Expenses - Amgen; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Sanofi |
Travel, Accommodations, Expenses - Janssen-Cilag; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Curevac; Dendreon; Ipsen; Janssen Oncology; Novartis; Orion; Sanofi; Takeda |
Speakers' Bureau - Amgen; Astellas Pharma; Janssen Oncology; Sanofi |
Travel, Accommodations, Expenses - Amgen |